Program
givastomig
Also written as “Givastomig”, “TJ033721 (givastomig)” and “TJ033721 (givastomig) , nivolumab, chemotherapy”.
Its studies are mostly in Neoplasm Metastasis, led by I-Mab Biopharma US.
Furthest: phase 2, since Feb 11, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| I-Mab Biopharma US | 22 open or running | phase 2since Feb 11, 2026 | May 20, 2021 | Dec 2026phase 1 · NCT04900818 |
Also a collaborator on its studies: Bristol-Myers Squibb.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2021First study: phase 1 study in Neoplasm MetastasisFirst studyNCT04900818 · 330 planned · United States, China
- Feb 11, 2026Phase 2 study in Neoplasm MetastasisPhase 2 reachedNCT07432295 · 180 planned · United States, China, Japan
Ahead
- Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT04900818
- Mar 2030Primary completion: phase 2 study in Neoplasm MetastasisNCT07432295
TargetBeta
CLDN18 →read by rule
“A bispecific antibody composed of a human, Fc-silenced immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07432295Neoplasm Metastasis · United States, China, Japan | 2 | Recruiting | Mar 2030 | 180 |
| NCT04900818Neoplasm Metastasis · United States, China | 1 | Recruiting | Dec 2026 | 330 |
How it is read
Names in the registry
- “Givastomig”, 1 entry
- “TJ033721 (givastomig)”, 1 entry
- “TJ033721 (givastomig) , nivolumab, chemotherapy”, 1 entry
- “TJ033721 (givastomig), chemotherapy”, 1 entry
- “TJ033721 (givastomig), durvalumab, chemotherapy”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.